Praxis Precision Medicines
Update in progressPRAX (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on CNS disorders marked by neuronal excitation–inhibition imbalance in the United States. It uses its Cerebrum small-molecule platform for orally available CNS therapies and Solidus to discover antisense oligonucleotides. Its pipeline includes ulixacaltamide, relutrigine, vormatrigine, and Elsunersen in NDA/Phase 2/3 trials, plus preclinical PRAX programs. Based in Boston, founded 2015.
Company score
- Sentiment
- 0.46
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.45
- Governance
- 0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.14
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.30
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!